Press Releases

BIOMS MEDICAL TO PRESENT AT ACUMEN BIOFIN RODMAN & RENSHAW 4TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

HIS NEWS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR TO ANY UNITED STATES WIRE SERVICE

Edmonton, Alberta, May 11, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Acumen BioFin Rodman and Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco.

WHEN: Monday, May 14th at 2:55pm (Local Time)
WHERE: Le Meridien Beach Plaza Hotel, Monte Carlo

About Acumen BioFin Rodman and Renshaw Global Healthcare Conference

The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.
For more information visit http://www.rodmanandrenshaw.com/

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.